USS Investment Management Ltd Cuts Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

USS Investment Management Ltd reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 7.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 18,202 shares of the biopharmaceutical company's stock after selling 1,440 shares during the period. USS Investment Management Ltd's holdings in Regeneron Pharmaceuticals were worth $12,969,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Voloridge Investment Management LLC bought a new position in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $151,105,000. Waverly Advisors LLC raised its holdings in Regeneron Pharmaceuticals by 23.0% in the 4th quarter. Waverly Advisors LLC now owns 1,280 shares of the biopharmaceutical company's stock valued at $912,000 after buying an additional 239 shares during the last quarter. Woodline Partners LP raised its holdings in Regeneron Pharmaceuticals by 3.9% in the 4th quarter. Woodline Partners LP now owns 103,279 shares of the biopharmaceutical company's stock valued at $73,569,000 after buying an additional 3,862 shares during the last quarter. Vestal Point Capital LP bought a new position in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $14,247,000. Finally, Victrix Investment Advisors bought a new position in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $3,490,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Down 1.4%

NASDAQ REGN traded down $8.51 during mid-day trading on Friday, hitting $588.34. The company's stock had a trading volume of 655,734 shares, compared to its average volume of 801,377. The company's 50 day simple moving average is $592.38 and its 200 day simple moving average is $674.96. Regeneron Pharmaceuticals, Inc. has a twelve month low of $520.50 and a twelve month high of $1,211.20. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $63.52 billion, a price-to-earnings ratio of 15.37, a PEG ratio of 2.34 and a beta of 0.43.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. During the same period in the previous year, the business posted $9.55 EPS. The business's revenue for the quarter was down 3.7% compared to the same quarter last year. Analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.60%. The ex-dividend date is Tuesday, May 20th. Regeneron Pharmaceuticals's payout ratio is currently 8.96%.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Wall Street Zen lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 1st. JPMorgan Chase & Co. dropped their price objective on shares of Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an "overweight" rating for the company in a report on Monday, March 31st. BMO Capital Markets dropped their price objective on shares of Regeneron Pharmaceuticals from $865.00 to $800.00 and set an "outperform" rating for the company in a report on Wednesday, April 30th. Wells Fargo & Company lowered their price target on shares of Regeneron Pharmaceuticals from $750.00 to $700.00 and set an "overweight" rating for the company in a report on Wednesday, April 30th. Finally, The Goldman Sachs Group lowered their price target on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, nineteen have assigned a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $890.60.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.